Amgen (AMGN) Suit No Surprise for Regeneron (REGN) - Analyst (SNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Amgen (AMGN) Files Patent Infringement Suit Against Sanofi (SNY), Regeneron (REGN)
October 17, 2014 9:02 AM EDTAmgen (NASDAQ: AMGN) announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi (NYSE: SNY), Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron")(Nasdaq:... More
